Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-22T18:21:59.748Z Has data issue: false hasContentIssue false
  • English
  • Français

ASPREE-D: Aspirin for the prevention of depression in the elderly

Published online by Cambridge University Press:  31 May 2016

Michael Berk ,
R. L. Woods ,
M. R. Nelson ,
R. C. Shah ,
C. M. Reid ,
E. Storey ,
S. M. Fitzgerald ,
J. E. Lockery ,
R. Wolfe  and
M. Mohebbi
...Show all authors
Michael Berk*
Affiliation:
Deakin University, School of Medicine, IMPACT Strategic Research Centre, Barwon Health, Geelong, Victoria, Australia School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia Department of Psychiatry, University of Melbourne, Parkville, Victoria, Australia Orygen Youth Health Research Centre, Parkville, Victoria, Australia
R. L. Woods
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
M. R. Nelson
Affiliation:
Menzies Institute for Medical Research, University of Tasmania, Tasmania, Australia
R. C. Shah
Affiliation:
Department of Family Medicine and the Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois, USA
C. M. Reid
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia School of Public Health, Curtin University, Perth, Western Australia, Australia
E. Storey
Affiliation:
Central Clinical School, Monash University, Victoria, Australia
S. M. Fitzgerald
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
J. E. Lockery
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
R. Wolfe
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
M. Mohebbi
Affiliation:
Deakin University, School of Medicine, IMPACT Strategic Research Centre, Barwon Health, Geelong, Victoria, Australia
A. M. Murray
Affiliation:
Berman Center for Outcomes & Clinical Research, Hennepin County Medical Center, Minneapolis, Minnesota, USA
B. Kirpach
Affiliation:
Berman Center for Outcomes & Clinical Research, Hennepin County Medical Center, Minneapolis, Minnesota, USA
R. Grimm
Affiliation:
Berman Center for Outcomes & Clinical Research, Hennepin County Medical Center, Minneapolis, Minnesota, USA
J. J. McNeil
Affiliation:
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
*
Correspondence should be addressed to: Michael Berk, IMPACT Strategic Research Centre, School of Medicine, Deakin University, 75 Pigdon's Road, Waurn Ponds, Geelong, Victoria 3216, Australia. Phone: +61 3 42153330. Email: [email protected].
Get access

Abstract

Background:

Not only is depression associated with increased inflammation but inflammation is a risk factor for the genesis of depression. Many of the environmental risk factors for depression are transduced through inflammatory signaling. Anti-inflammatory agents show promise for the management of depression in preclinical, epidemiological, and early clinical studies. This opens the door to the potential for anti-inflammatory agents to treat and prevent depression. There are no evidence-based pharmacotherapies for depression prevention.

Method:

ASPREE-D, aspirin in the prevention of depression in the elderly, is a sub study of ASPREE, which explores the potential of aspirin to prevent a range of inflammation related disorders in the elderly. With a sample size of 19,114, and a duration of 5 years, this placebo controlled study will be one of the largest randomized controlled trials in psychiatry and will provide definitive evidence on the ability of aspirin to prevent depression.

Results:

This paper presents the rationale for the study and presents a summary of the study design.

Conclusions:

ASPREE-D may not only define novel therapy but will provide mechanistic proof of concept of the role of inflammation in depression.

Keywords

immunologyantidepressantsbiomarkersaspirininflammationriskpreventiondepression
Type
Protocol-only paper
Information
International Psychogeriatrics , Volume 28 , Issue 10 , October 2016 , pp. 1741 - 1748
Copyright
Copyright © International Psychogeriatric Association 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alexopoulos, G. S. (2005). Depression in the elderly. Lancet, 365, 1961–1970.Google Scholar
Almeida, O. P., Alfonso, H., Jamrozik, K., Hankey, G. J. and Flicker, L. (2010). Aspirin use, depression, and cognitive impairment in later life: the health in men study. Journal of the American Geriatrics Society, 58, 990–992.Google Scholar
Ancill, R. J. and Holliday, S. G. (1990). Treatment of depression in the elderly: a Canadian view. Prog Neuropsychopharmacol Biol Psychiatry, 14, 655–661.Google Scholar
ASPREE Investigator Group (2013). Study design of ASPirin in reducing events in the elderly (ASPREE): a randomized, controlled trial. Contemporary Clinical Trials, 36, 555–564.Google Scholar
Australian Government, NHMRC. (2007). National Statement on Ethical Conduct in Human Research (2007) - Updated May 2015. Available at: https://www.nhmrc.gov.au/guidelines-publications/e72.Google Scholar
Berk, M. et al. (2013). Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Medicine, 11, 74.Google Scholar
Brunello, N. et al. (2006). Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in the chronic escape deficit model of depression. International Clinical Psychopharmacology, 21, 219–225.CrossRefGoogle ScholarPubMed
Chen, Y. G. et al. (2006). Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chinese Medical Journal (Engl), 119, 32–36.Google Scholar
Cuijpers, P., van Straten, A., Smit, F., Mihalopoulos, C. and Beekman, A. (2008). Preventing the onset of depressive disorders: a meta-analytic review of psychological interventions. American Journal of Psychiatry, 165, 1272–1280.Google Scholar
Dean, B., Tawadros, N., Scarr, E. and Gibbons, A. S. (2010). Regionally-specific changes in levels of tumour necrosis factor in the dorsolateral prefrontal cortex obtained postmortem from subjects with major depressive disorder. Journal of Affective Disorders, 120, 245–248.Google Scholar
Dozeman, E., van Schaik, D. J., van Marwijk, H. W., Stek, M. L., van der Horst, H. E. and Beekman, A. T. (2011). The center for epidemiological studies depression scale (CES-D) is an adequate screening instrument for depressive and anxiety disorders in a very old population living in residential homes. International Journal of Geriatric Psychiatry, 26, 239–246.Google Scholar
Fisher, M., Cushman, M., Knappertz, V. and Howard, G. (2008). An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration. American Heart Journal, 156, 106–111.Google Scholar
Gao, X. R. et al. (2009). Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. Journal of Pharmacy and Pharmacology, 61, 1505–1510.Google Scholar
Ghubash, R., Daradkeh, T. K., Al Naseri, K. S., Al Bloushi, N. B. and Al Daheri, A. M. (2000). The performance of the center for epidemiologic study depression scale (CES-D) in an Arab female community. International Journal of Social Psychiatry, 46, 241–249.Google Scholar
Hiles, S. A., Baker, A. L., de Malmanche, T. and Attia, J. (2012). A meta-analysis of differences in IL-6 and IL-10 between people with and without depression: exploring the causes of heterogeneity. Brain Behavior and Immunity, 26, 1180–1188.Google Scholar
Ikonomidis, I., Andreotti, F., Economou, E., Stefanadis, C., Toutouzas, P. and Nihoyannopoulos, P. (1999). Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation, 100, 793–798.Google Scholar
Jenny, N. S. et al. (2012). Long-term assessment of inflammation and healthy aging in late life: the cardiovascular health study all stars. The Journals of Gerontology, Series A Biological Sciences and Medical Sciences, 67, 970–976.CrossRefGoogle Scholar
Krishnadas, R. and Cavanagh, J. (2012). Depression: an inflammatory illness? Journal of Neurology, Neurosurgery & Psychiatry, 83, 495–502.Google Scholar
Liu, Y., Ho, R. C. and Mak, A. (2012). Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. Journal of Affective Disorders, 139, 230–239.Google Scholar
Maes, M. et al. (2012a). Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Medicine, 10, 66.Google Scholar
Maes, M., Fisar, Z., Medina, M., Scapagnini, G., Nowak, G. and Berk, M. (2012b). New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates–Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 20, 127–150.Google Scholar
Mendlewicz, J., Kriwin, P., Oswald, P., Souery, D., Alboni, S. and Brunello, N. (2006). Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. International Clinical Psychopharmacology, 21, 227–231.CrossRefGoogle ScholarPubMed
Moylan, S., Maes, M., Wray, N. R. and Berk, M. (2013). The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Molecular Psychiatry, 18, 595–606.Google Scholar
O'Neil, A. et al. (2015) A shared framework for the common mental disorders and non-communicable disease: key considerations for disease prevention and control. BMC Psychiatry. 5, 15.Google Scholar
Palsson, S. P., Ostling, S. and Skoog, I. (2001). The incidence of first-onset depression in a population followed from the age of 70 to 85. Psychological Medicine, 31, 1159–1168.Google Scholar
Pasco, J. A. et al. (2010a). Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychotherapy and Psychosomatics, 79, 323–325.Google Scholar
Pasco, J. A. et al. (2010b). Association of high-sensitivity C-reactive protein with de novo major depression. British Journal of Psychiatry, 197, 372–377.Google Scholar
Tuunainen, A., Langer, R. D., Klauber, M. R. and Kripke, D. F. (2001). Short version of the CES-D (Burnam screen) for depression in reference to the structured psychiatric interview. Psychiatry Research, 103, 261–270.Google Scholar
Wang, Y., Yang, F., Liu, Y. F., Gao, F. and Jiang, W. (2011). Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neuroscience Letters, 499, 74–79.Google Scholar